Precision Drilling's investment case hinges on its ability to convert operational scale into free cash flow despite a challenging drilling environment. The company has demonstrated robust cash generation, with operating cash flow of $145.6M in 2026Q2 against a...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 28, 2026 | -$0.38-188.4% vs $0.43 | $319M+2.6% vs $311M |
Q2 2026 Apr 29, 2026 | $0.98-43.4% vs $1.73 | $378M+3.5% vs $365M |
Q1 2026 Feb 11, 2026 | -$2.34-257.4% vs $1.49 | $348M-2.4% vs $357M |
Q4 2025 Oct 22, 2025 | -$0.55-152.3% vs $1.06 | $332M-0.4% vs $333M |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CALGARY, Alberta, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2026 third quarter results after the market closes on Tuesday, October 27, 2026, and has scheduled a conference call to begin at 11:00 a.m. MT (1:00 p.m. ET) on the next day, Wednesday, October 28, 2026.
39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for PDS0101 PRINCETON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of results from a Phase 2 trial evaluating PDS0101, its HPV16-targeted immunotherapy, in combination with pembrolizumab in the September 17, 2026, issue of JAMA Oncology, a peer reviewed journal of the American Medical Association.
On September 16, 2026, Precision Drilling Corp (PDS) shares fell 3.8% to $86.03, continuing a downward trend over the past week. The stock has fluctuated betwee
Benchmark PDS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Precision Drilling Corporation (PDS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $83.80 | $1.08B | 851.59 | -3.08% | 0.1% | 0.11% | — | |
| $38.20 | $3.82B | -23.01 | 35.89% | -3.44% | -5.08% | — | |
| $79.83 | $1.18B | 4.65 | 8.69% | 6.52% | 14.25% | — | |
| $11.30 | $4.29B | -47.08 | -10.25% | -1.92% | -2.81% | — | |
| $7.42 | $103.51M | -5.94 | 1.41% | 12.66% | 514.81% | — | |
| $20.03 | $2.77B | 100.15 | -3.08% | 2.24% | 3.11% | — |
Precision Drilling Corporation (PDS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when PDS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Precision Drilling Corporation (PDS) stock FAQ — growth, dividends, profitability & financials explained
Precision Drilling Corporation (PDS) reported $1.92B in revenue for fiscal year 2025. This represents a 1077% increase from $163.1M in 1996.
Precision Drilling Corporation (PDS) saw revenue decline by 3.1% over the past year.
Precision Drilling Corporation (PDS) reported a net loss of $32.8M for fiscal year 2025.
Precision Drilling Corporation (PDS) has a return on equity (ROE) of 0.1%. This is below average, suggesting room for improvement.
Precision Drilling Corporation (PDS) generated $118.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
